U.S.A. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson’s single-dose COVID-19 vaccine after six recipients developed a rare disorder involving blood clots.
The U.S.A. Centers for Disease Control and Prevention will hold an advisory meeting on Wednesday to review the cases.
The CDC and the U.S.A. Food and Drug Administration said in a joint statement that the adverse events appear to be extremely rare right now.
The company’s shares were down 3% before the opening bell.
The move from the U.S.A. regulators comes less than a week after Europe’s drugs regulator said it was reviewing rare blood clots in four people in the United States who received the shot.